SRC-2 depletion, which elevates SIRT3 levels, markedly reduces metastasis, particularly in bone, underscoring the therapeutic potential of targeting this AR-SRC-2-SIRT3 axis in PCa treatment. Here, SIRT3 is linked to posterior cortical atrophy.